Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral docetaxel with cyclosporin A in advanced breast cancer
ISRCTN90476883Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 1998
- Modality
- Small Molecules, Peptides, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel and cyclosporine in breast cancer (3 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Safety assessments and Pharmacokinetics. Started Oct 1998; status: completed.
02
Drugs
docetaxelcyclosporine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN90476883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN90476883.